Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 39-46

  Lu, J P ^a,b   Monardo, L ^b   Bryskin, I ^c   Hou, Z F ^b   Trachtenberg, J ^c   Wilson, B C ^c   Pinthus, J H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgens; NADPH oxidase; NOX; Oxidative stress; Radiation; Testosterone

Indexed keywords

ANDROGEN; BICALUTAMIDE; ENZYME INHIBITOR; GLYCOPROTEIN GP 91; PROTEIN P22; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY;

ACETOPHENONES; ACETYLCYSTEINE; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; METRIBOLONE; MICE; NADPH OXIDASE; NEOPLASM TRANSPLANTATION; NITRILES; ONIUM COMPOUNDS; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; TOSYL COMPOUNDS;

EID: 76949089190     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.24     Document Type: Article

References (31)

1. Nichol A, Chung P, Lockwood G, Rosewall T, Divanbiegi L, Sweet J et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 2005; 76: 11-17.
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
3. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244.
5. Woodward WA, Wachsberger P, Burd R, Dicker AP. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer Prostatic Dis 2005; 8: 127-132.
6. Lorenzo PI, Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 2008; 10: 418-428.
7. Lawton CA. Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. Semin Radiat Oncol 2003; 13: 141-151.
8. Pinthus JH, Bryskin I, Trachtenberg J, Lu JP, Singh G, Fridman E, Wilson BC. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia 2007; 9: 68-80.
9. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785.
10. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
11. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore. Trends Biochem Sci 2003; 28: 502-508.
12. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004; 279: 34643-34654.
13. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994; 54: 6049-6052.
14. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004; 114: 1774-1781.
15. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Casodex 10-200mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 1998; 33: 39-53.
16. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A et al. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000; 60: 6563-6567.
17. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003; 6: 73-85.
18. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 2003; 285: C353-C369.
19. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L et al. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005; 62: 200-207.
20. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 2002; 99: 715-720.
21. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003; 163: 2513-2522.
22. Gonzales RJ, Duckles SP, Krause DN. Dihydrotestosterone stimulates cerebrovascular inflammation through NFkappaB, modulating contractile function. J Cereb Blood Flow Metab 2009; 29: 244-253.
23. Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006; 281: 5657-5667.
24. Juliet PA, Hayashi T, Daigo S, Matsui-Hirai H, Miyazaki A, Fukatsu A et al. Combined effect of testosterone and apocynin on nitric oxide and superoxide production in PMA-differentiated THP-1 cells. Biochim Biophys Acta 2004; 1693: 185-191.
25. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176.
26. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-252.
27. Selemidis S, Sobey CG,Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008; 120: 254-291.
28. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994; 11: 95-102.
29. Simons JM, Hart BA, Ip Vai Ching TR, Van Dijk H, Labadie RP. Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils. Free Radic Biol Med 1990; 8: 251-258.
30. Van den Worm E, Beukelman CJ, Van den Berg AJ, Kroes BH, Labadie RP, Van Dijk H. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur J Pharmacol 2001; 433: 225-230.
31. Yu J, Weïwer M, Linhardt RJ, Dordick JS. The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol 2008; 6: 204-217.